MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Movement disorder practice in a rural setting: challenges and opportunities and utility of telemedicine

    P. Karau, R. Mbijiwe (Meru, Kenya)

    Objective: To describe the experience of a movement disorder practice in a rural setting, the role of telehealth and the conditions diagnosed and managed Background:…
  • 2022 International Congress

    Malignant catatonia secondary to clozapine withdrawal: A case report

    T. Thammongkolchai, P. Termsarasab (Bangkok, Thailand)

    Objective: To report a patient with malignant catatonia from abrupt clozapine discontinuation. Background: Clozapine blocks 5HT2A/5HT2C serotonin and dopamine receptors. Cholinergic and serotoninergic rebounds have…
  • 2022 International Congress

    Dried blood and plasma spots for the measurement of neurofilament light chain and inflammatory cytokines in patients with REM sleep behaviour disorder

    B. Huxford, C. Simonet, L. Carbonell, A. Zirra, N. Vickaryous, A. Gill, A. Schrag, R. Dobson, A. Noyce (London, United Kingdom)

    Objective: The objective of this study was to investigate the relationship between plasma and dried blood/ plasma spot measurements of inflammatory markers (IFN-ɣ, IL-1β, IL-6,…
  • 2022 International Congress

    Choice of shoulder muscles for the multi-pattern treatment of upper limb spasticity with botulinum neurotoxin injections

    J. Jacinto (Alcabideche, Portugal)

    Objective: To present an experts’ consensus on the use of botulinum neurotoxin (BoNT) injections in the multi-pattern treatment of shoulder spasticity to increase awareness of…
  • 2022 International Congress

    Serum Metabolomic Characterization of PLA2G6-associated Dystonia-Parkinsonism: a case-control biomarker study

    C. Chen, M. Lou, Y. Sun, W. Wang, J. Wang (Shanghai, China)

    Objective: PLA2G6 is the causative gene for autosomal recessive Dystonia-Parkinsonism (PARK14). This case-control biomarker study aimed to test serum metabolomics of patients diagnosed as PARK14.…
  • 2022 International Congress

    Performance of oral diadochokinesis in Parkinson’s Disease motor subtypes

    V. Dos Santos, R. Rothe-Neves,, A. Bressanelli, I. Klein, M. Olchik (Porto Alegre, Brazil)

    Objective: To compare the performance of the oral diadochokinesis task in the different motor subtypes of PD (postural instability/gait difficulty - PIGD, tremor-dominant - TD,…
  • 2022 International Congress

    Cannabis treatment in patients with Huntington’s disease in a clinic cohort was safe and effective

    N. Omer, A. Bar David, N. Geva, Y. Zlotnik, T. Gurevich, S. Essa (Tel-Aviv, Israel)

    Objective: To estimate the safety and efficacy of Cannabis treatment in HD patients. Background: Huntington's disease (HD) is a neurodegenerative progressive disorder inherited in an…
  • 2022 International Congress

    MPTP-induced structural reorganization of neurons in mice Basal Ganglia: Verifying the sequelae of differential toxicity

    B. Bhaduri, I. Datta, R. Yadav, D. Srinivas, P. Alladi (Bangalore, India)

    Objective: To evaluate the changes in the neuronal arborization of the medium spiny neurons of striatum & substantia nigra neurons,  in response to MPTP in…
  • 2022 International Congress

    Beneficial effects of cinnamaldehyde in orofacial dyskinesia in haloperidol-induced rat model

    S. -, V. Parcha (Dehardun, India)

    Objective: This investigation evaluates the effect of CA in orofacial dyskinesia in haloperidol-induced rat male model Background: Orofacial dyskinesias are involuntary repetitive movements of the…
  • 2022 International Congress

    Expanding the armamentarium of clinical use of apomorphine in movement disorders.

    S. Bansal, JR. Chai, M. Jog (London, Canada)

    Objective: To demonstrate the use of subcutaneous(SC) apomorphine injections in suspected untreated dopamine responsive conditions. Background: Apomorphine is a dopamine agonist historically used in dopamine…
  • « Previous Page
  • 1
  • …
  • 789
  • 790
  • 791
  • 792
  • 793
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley